Related references
Note: Only part of the references are listed.Impact of Enzyme Replacement Therapy on Linear Growth in Korean Patients with Mucopolysaccharidosis Type II (Hunter Syndrome)
Sung Yoon Cho et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2014)
Assessment of hearing loss by pure-tone audiometry in patients with mucopolysaccharidoses
Hsiang-Yu Lin et al.
MOLECULAR GENETICS AND METABOLISM (2014)
Cardiovascular abnormalities in Taiwanese patients with mucopolysaccharidosis
Shan-Miao Lin et al.
MOLECULAR GENETICS AND METABOLISM (2014)
Natural history and clinical assessment of Taiwanese patients with mucopolysaccharidosis IVA
Hsiang-Yu Lin et al.
ORPHANET JOURNAL OF RARE DISEASES (2014)
Characterization of Pulmonary Function Impairments in Patients With Mucopolysaccharidoses-Changes With Age and Treatment
Shuan-Pei Lin et al.
PEDIATRIC PULMONOLOGY (2014)
Mucopolysaccharidosis: Cardiologic features and effects of enzyme-replacement therapy in 24 children with MPS I, II and VI
Marion M. M. G. Brands et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2013)
Plasma and urinary levels of dermatan sulfate and heparan sulfate derived disaccharides after long-term enzyme replacement therapy (ERT) in MPS I: correlation with the timing of ERT and with total urinary excretion of glycosaminoglycans
Minke H. de Ru et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2013)
Assessment of bone mineral density by dual energy x-ray absorptiometry in patients with mucopolysaccharidoses
Hsiang-Yu Lin et al.
ORPHANET JOURNAL OF RARE DISEASES (2013)
Enzyme replacement therapy (ERT) procedure for mucopolysaccharidosis type II (MPS II) by intraventricular administration (IVA) in murine MPS II
Takashi Higuchi et al.
MOLECULAR GENETICS AND METABOLISM (2012)
Analysis of Glycosaminoglycans in Cerebrospinal Fluid from Patients with Mucopolysaccharidoses by Isotope-Dilution Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry
Haoyue Zhang et al.
CLINICAL CHEMISTRY (2011)
Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI
Christiane Auray-Blais et al.
MOLECULAR GENETICS AND METABOLISM (2011)
Enzyme replacement therapy for mucopolysaccharidosis VI-experience in Taiwan
Hsiang-Yu Lin et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2010)
Long-term Efficacy and Safety of Laronidase in the Treatment of Mucopolysaccharidosis I
Lorne A. Clarke et al.
PEDIATRICS (2009)
Mucopolysaccharidosis I: Management and Treatment Guidelines
Joseph Muenzer et al.
PEDIATRICS (2009)
Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years:: Results of a multinational study of recombinant human α-L-iduronidase (Laronidase)
J. Edmond Wraith et al.
PEDIATRICS (2007)
Mucopolysaccharidosis I under enzyme replacement therapy with laronidase - A mortality case with autopsy report
HY Lin et al.
JOURNAL OF INHERITED METABOLIC DISEASE (2005)
The first 5 years of clinical experience with laroniclase enzyme replacement therapy for mucopolysacchariclosis I
JE Wraith
EXPERT OPINION ON PHARMACOTHERAPY (2005)
Enzyme replacement therapy for mucopolysaccharidosis I:: A randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (Laronidase)
JE Wraith et al.
JOURNAL OF PEDIATRICS (2004)
Share Paper
